PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Inclusion Criteria: * Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma (histology confirmed by MSKCC Department of Pathology) * Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or other tumor response criteria from an MSKCC IRB-approved clinical research protocol. * This does not apply to patients with myeloproliferative neoplasm. The presence of active myeloproliferative neoplasm will be determined by applicable disease specific diagnostic criteria and patient assessment by the patient's oncologist and trial investigators (eg, manifestations of active MPN such as splenomegaly, abnormal blood counts, etc). * Age between 18-90 * Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential * No breast-feeding Exclusion Criteria: * Previous allergic reaction to contrast medium. * Hypersensitivity to iodide products. * Known hyperthyroidism Hepatic: * Bilirubin \> 1.5 x institutional upper limit of normal (ULN) * AST/ALT \>2.5 x ULN * Albumin \< 2 g/dl * GGT \> 2.5 x ULN IF Alkaline phosphatase \> 2.5 x ULN. Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min. * Positive serum pregnancy test for females * Acute major illness (e.g., infection, unstable cardiovascular condition, etc.)